Agammaglobulinemia: Causative mutations and their implications for novel therapies

Expert Review of Clinical Immunology

Volumn 9, Issue 12, 2013, Pages 1205-1221

  Berglöf, Anna ^a   Turunen, Janne J ^a   Gissberg, Olof ^a   Bestas, Burcu ^a   Blomberg, K Emelie M ^a   Smith, Cl Edvard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Agammaglobulinemia; ARA; B cell; Gene therapy; Mouse models; Splicing; XLA

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD79A ANTIGEN; CD79B ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN TYROSINE KINASE; ZINC FINGER NUCLEASE;

AGAMMAGLOBULINEMIA; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; DNA BINDING MOTIF; GENE FUNCTION; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC DISORDER; GENETIC TRANSCRIPTION; HEMOPHILIA B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RATE; NONHUMAN; PLURIPOTENT STEM CELL; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; REVIEW; SPONTANEOUS MUTATION; TRANS SPLICING; X LINKED AGAMMAGLOBULINEMIA;

AGAMMAGLOBULINEMIA; ANIMALS; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN SPLICING; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84887925566     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.850030     Document Type: Review

References (102)

1. Bousfiha AA, Jeddane L, Ailal F et al. A phenotypic approach for IUIS PID classification and diagnosis: Guidelines for clinicians at the bedside. J. Clin. Immunol. 33(6), 1078-1087 (2013
2. Conley ME, Broides A, Hernandez-Trujillo V et al. Genetic analysis of patients with defects in early B-cell development. Immunol. Rev. 203, 216-34 (2005
3. Primary immunodeficiency diseases: A molecular & cellular approach. (3rd Edition). Ochs H, Smith C, Puck J (Eds). Oxford University Press, New York, USA
4. Winkelstein JA, Marino MC, Lederman HM et al. X-linked agammaglobulinemia: Report on a United States registry of 201 patients. Medicine 85(4), 193-202 (2006
5. Conley ME, Dobbs AK, Farmer DM et al. Primary B cell immunodeficiencies: Comparisons and contrasts. Ann. Rev. Immunol. 27, 199-227 (2009
6. Vetrie D, Vorechovský I, Sideras P et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361(6409), 226-233 (1993
7. Tsukada S, Saffran DC, Rawlings DJ et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72(2), 279-290 (1993
8. Lindvall JM, Blomberg KEM, Väliaho J et al. Bruton's tyrosine kinase: Cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203, 200-215 (2005
9. Noordzij JG, de Bruin-Versteeg S, Hartwig NG et al. XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts. J. Clin. Immunol. 22(5), 306-318 (2002
10. Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME. Mutations in the human l5/14.1 gene result in B cell deficiency and agammaglobulinemia. J. Exp. Med. 187(1), 71-77 (1998
11. Yel L, Minegishi Y, Coustan-Smith E et al. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N. Engl. J. Med. 335(20), 1486-1493 (1996
12. Minegishi Y, Coustan-Smith E, Rapalus L, Ersoy F, Campana D, Conley ME. Mutations in Iga(CD79a) result in a complete block in B-cell development. J. Clin. Invest. 104(8), 1115-1121 (1999
13. Ferrari S, Lougaris V, Caraffi S et al. Mutations of the Igb gene cause agammaglobulinemia in man. J. Exp. Med. 204(9), 2047-2051 (2007
14. Dobbs AK, Yang T, Farmer D, Kager L, Parolini O, Conley ME. Cutting edge: A hypomorphic mutation in Igb (CD79b) in a patient with immunodeficiency and a leaky defect in B cell development. J. Immunol. 179(4), 2055-2059 (2007
15. Minegishi Y, Rohrer J, Coustan-Smith E et al. An essential role for BLNK in human B cell development. Science 286(5446), 1954-1957 (1999
16. Conley ME, Dobbs AK, Quintana AM et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85a subunit of PI3K. J. Exp. Med. 209(3), 463-70 (2012
17. Dobbs AK, Bosompem A, Coustan-Smith E, Tyerman G, Saulsbury FT, Conley ME. Agammaglobulinemia associated with BCR-B cells and enhanced expression of CD19. Blood 118(7), 1828-1837 (2011
18. Van Zelm MC, Reisli I, Van Der Burg M et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354(18), 1901-1912 (2006
19. Van Zelm MC, Geertsema C, Nieuwenhuis N et al. Gross deletions involving IGHM, BTK, or Artemis: A model for genomic lesions mediated by transposable elements. Am. J. Hum. Genet. 82(2), 320-332 (2008
20. Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25(6), 1317-1318 (1997
21. Nodland SE, Berkowska MA, Bajer AA et al. IL-7R expression and IL-7 signaling confer a distinct phenotype on developing human B-lineage cells. Blood 118(8), 2116-2127 (2011
22. Conley ME, Rohrer J, Rapalus L, Boylin EC, Minegishi Y. Defects in early Bcell development: Comparing the consequences of abnormalities in pre-BCR signaling in the human and the mouse. Immunol. Rev. 178, 75-90 (2000
23. Khan WN, Alt FW, Gerstein RM et al. Defective B cell development and function in Btk-deficient mice. Immunity 3(3), 283-299 (1995
24. Berglöf A, Sandstedt K, Feinstein R, Bölske G, Smith CIE. B cell-deficient muMT mice as an experimental model for Mycoplasma infections in X-linked agammaglobulinemia. Eur. J. Immunol. 27(8), 2118-2121 (1997
25. Ellmeier W, Jung S, Sunshine MJ et al. Severe B cell deficiency in mice lacking the tec kinase family members Tec and Btk. J. Exp. Med. 192(11), 1611-1624 (2000
26. Kitamura D, Rajewsky K. Targeted disruption of m chain membrane exon causes loss of heavy-chain allelic exclusion. Nature 356(6365), 154-156 (1992
27. Pelanda R, Braun U, Hobeika E, Nussenzweig MC, Reth M. B cell progenitors are arrested in maturation but have intact VDJ recombination in the absence of Ig-a and Ig-b. J. Immunol. 169(2), 865-872 (2002
28. Gong S, Nussenzweig MC. Regulation of an early developmental checkpoint in the B cell pathway by Igb. Science 272(5260), 411-414 (1996
29. Kitamura D, Kudo A, Schaal S, Müller W, Melchers F, Rajewsky K. A critical role of l5 protein in B cell development. Cell 69(5), 823-831 (1992
30. Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic- specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv. Immunol. 79, 93-128 (2001
31. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3(1), 39-50 (1995
32. Maas A, Dingjan GM, Grosveld F, Hendriks RW. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J. Immunol. 162(11), 6526-6533 (1999
33. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc. Natl Acad. Sci. USA. 94(24), 13152-13157 (1997
34. Drabek D, Raguz S, De Wit TP et al. Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region. Proc. Natl Acad. Sci. USA 94(2), 610-615 (1997
35. Maas A, Dingjan GM, Savelkoul HF, Kinnon C, Grosveld F, Hendriks RW. The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome transgene. Eur. J. Immunol. 27(9), 2180-2187 (1997
36. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 270(5237), 794-797 (1995
37. Fruman DA, Satterthwaite AB, Witte ON. Xid-like phenotypes: A B cell signalosome takes shape. Immunity 13(1), 1-3 (2000
38. Yamazaki T, Takeda K, Gotoh K, Takeshima H, Akira S, Kurosaki T. Essential immunoregulatory role for BCAP in B cell development and function. J. Exp. Med. 195(5), 535-545 (2002
39. Ombrello MJ, Remmers EF, Sun G et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366(4), 330-338 (2012
40. Hendriks RW, Middendorp S. The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol. 25(5), 249-56 (2004
41. Kurosaki T. Regulation of BCR signaling. Mol. Immunol. 48(11), 1287-1291 (2011
42. Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin. Exp. Neuroimmunol. 164(Suppl.) 16-19 (2011
43. Howard V, Myers LA, Williams DA, et al. Stem cell transplants for patients with Xlinked agammaglobulinemia. Clin. Immunol. 107(2), 98-102 (2003
44. Segal DJ, Meckler JF. Genome Engineering at the Dawn of the Golden Age. Annu. Rev. Genomics Hum Genet. 14, 135-158 (2013
45. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat. Immunol. 11(6), 457-460 (2010
46. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 -an update. J. Gene Med. 15(2), 65-77 (2013
47. Moreau T, Barlogis V, Bardin F et al. Development of an enhanced B-specific lentiviral vector expressing BTK: A tool for gene therapy of XLA. Gene Ther. 15(12), 942-952 (2008
48. Yu PW, Tabuchi RS, Kato RM et al. Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer. Blood 104(5), 1281-1290 (2004
49. Kerns HM, Ryu BY, Stirling B V et al. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia. Blood 115(11), 2146-2155 (2010
50. Ng YY, Baert MR, Pike-Overzet K et al. Correction of B-cell development in Btkdeficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia 24(9), 1617-1630 (2010
51. Li L, Krymskaya L, Wang J et al. Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger Nucleases. Mol. Ther. 21(6), 1259-1269 (2013
52. Ellis BL, Hirsch ML, Porter SN, Samulski RJ, Porteus MH. Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs. Gene Ther. 20(1), 35-42 (2013
53. Lombardo A, Cesana D, Genovese P et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat. Methods 8(10), 861-869 (2011
54. Wood AJ, Lo TW, Zeitler B et al. Targeted genome editing across species using ZFNs and TALENs. Science 333(6040), 307 (2011
55. Hockemeyer D, Wang H, Kiani S et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29(8), 731-734 (2011
56. Li H, Haurigot V, Doyon Y et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475(7355), 217-221 (2011
57. Mali P, Yang L, Esvelt KM et al. RNAguided human genome engineering via Cas9. Science 339(6121), 823-826 (2013
58. Cong L, Ran FA, Cox D et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121), 819-823 (2013
59. Kim E, Kim S, Kim DH, Choi B-S, Choi I-Y, Kim J-S. Precision genome engineering with programmable DNAnicking enzymes. Genome Res. 22(7), 1327-1333 (2012
60. Havens MA, Duelli DM, Hastings ML. Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev. RNA 4(3), 247-266 (2013
61. Lopez-Herrera G, Berron-Ruiz L, Mogica-Martinez D, Espinosa-Rosales F, Santos-Argumedo L. Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia. Mol. Immunol. 45(4), 1094-1098 (2008
62. Kralovicova J, Hwang G, Asplund AC, Churbanov A, Smith CIE, Vorechovsky I. Compensatory signals associated with the activation of human GC 5' splice sites. Nucleic Acids Res. 39(16), 7077-7091 (2011
63. Cirak S, Arechavala-Gomeza V, Guglieri M et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, doseescalation study. Lancet 378(9791), 595-605 (2011
64. Goemans NM, Tulinius M, van den Akker JT et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364(16), 1513-1522 (2011
65. Douglas AGL, Wood MJA. Splicing therapy for neuromuscular disease. Mol. Cell Neurosci. 56C, 169-185 (2013
66. Pinotti M, Balestra D, Rizzotto L, Maestri I, Pagani F, Bernardi F. Rescue of coagulation factor VII function by the U1+5A snRNA. Blood 113(25), 6461-6464 (2009
67. Fernandez Alanis E, Pinotti M, Dal Mas A et al. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum. Mol. Genet. 21(11), 2389-2398 (2012
68. Owen N, Zhou H, Malygin AA et al. Design principles for bifunctional targeted oligonucleotide enhancers of splicing. Nucleic Acids Res. 39(16), 7194-7208 (2011
69. Chao H, Mansfield SG, Bartel RC et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA transsplicing. Nat. Med. 9(8), 1015-1019 (2003
70. Cooray S, Howe SJ, Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol. 507, 29-57 (2012
71. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene (2013
72. Sather BD, Ryu BY, Stirling B V et al. Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders. Mol. Ther. 19(3), 515-525 (2011
73. Suerth JD, Maetzig T, Brugman MH et al. Alpharetroviral self-inactivating vectors: Long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther. 20(5), 1022-1032 (2012
74. Nienhuis AW. Development of gene therapy for blood disorders: An update. Blood 122(9), 1556-1564 (2013
75. Di Matteo M, Belay E, Chuah MK, VandenDriessche T. Recent developments in transposon-mediated gene therapy. Expert Opin. Biol. Ther. 12(7), 841-858 (2012
76. Hackett PB, Largaespada DA, Switzer KC, Cooper LJN. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl. Res. 161(4), 265-283 (2013
77. Lopez Granados E, Porpiglia AS, Hogan MB, et al. Clinical and molecular analysis of patients with defects in m heavy chain gene. J. Clin. Invest. 110(7), 1029-1035 (2002
78. Väliaho J, Smith CIE, Vihinen M. BTKbase: The mutation database for X-linked agammaglobulinemia. Hum. Mutat. 27(12), 1209-1217 (2006
79. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 481(7381), 295-305 (2012
80. Hanna J, Wernig M, Markoulaki S et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318(5858), 1920-1923 (2007
81. Panopoulos AD, Belmonte JC. Induced pluripotent stem cells in clinical hematology: Potentials, progress, and remaining obstacles. Curr. Opin. Hematol. 19(4), 256-260 (2012
82. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 474(7350), 212-215 (2011
83. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell. 7(4), 521-531 (2010
84. Bar-Nur O, Russ HA, Efrat S, Benvenisty N. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 9(1), 17-23 (2011
85. Abad M, Mosteiro L, Pantoja C et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature doi:10.1038/ nature12586 (2013) (Epub ahead of print
86. Rais Y, Zviran A, Geula S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature doi:10.1038/nature 12587 (2013) (Epub ahead of print
87. Limon JJ, Fruman DA. Akt and mTOR in B Cell Activation and Differentiation. Front Immunol. 3, 228 (2012
88. Schuman J, Chen Y, Podd A et al. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kB activation. Blood 113(19), 4566-4574 (2009
89. Samuelson EM, Laird RM, Maue AC, Rochford R, Hayes SM. Blk haploinsufficiency impairs the development, but enhances the functional responses, of MZ B cells. Immunol. Cell Biol. 90(6), 620-629 (2012
90. Pappu BP, Lin X. Potential role of CARMA1 in CD40-induced splenic B cell proliferation and marginal zone B cell maturation. Eur. J. Immunol. 36(11), 3033-3043 (2006
91. Winslow MM, Gallo EM, Neilson JR, Crabtree GR. The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity 24(2), 141-152 (2006
92. Yasuda T, Sanjo H, Pagès G et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 28(4), 499-508 (2008
93. Dengler HS, Baracho G V, Omori SA et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat. Immunol. 9(12), 1388-1398 (2008
94. Hinman RM, Nichols WA, Diaz TM, Gallardo TD, Castrillon DH, Satterthwaite AB. Foxo3-/-mice demonstrate reduced numbers of pre-B and recirculating B cells but normal splenic B cell sub-population distribution. Int. Immunol. 21(7), 831-842 (2009
95. Chaimowitz NS, Falanga YT, Ryan JJ, Conrad DH. Fyn kinase is required for optimal humoral responses. PloS ONE 8(4), e60640 (2013
96. Hibbs ML, Tarlinton DM, Armes J et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 83(2), 301-311 (1995
97. Saijo K, Schmedt C, Su I-H et al. Essential role of Src-family protein tyrosine kinases in NF-kB activation during B cell development. Nat. Immunol. 4(3), 274-279 (2003
98. Coughlin JJ, Stang SL, Dower NA, Stone JC. RasGRP1 and RasGRP3 regulate B cell proliferation by facilitating B cell receptor-Ras signaling. J. Immunol. 175(11), 7179-7184 (2005
99. Turner M, Gulbranson-Judge A, Quinn ME, Walters AE, MacLennan IC, Tybulewicz VL. Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J. Exp. Med. 186(12), 2013-2021 (1997
100. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378(6554), 303-306 (1995
101. Tedford K, Nitschke L, Girkontaite I et al. Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling. Nat. Immunol. 2(6), 548-55 (2001
102. Mundt C, Licence S, Shimizu T, Melchers F, Mårtensson IL. Loss of precursor B cell expansion but not allelic exclusion in VpreB1/VpreB2 doubledeficient mice. J. Exp. Med. 193(4), 435-445 (2001